220 related articles for article (PubMed ID: 29398096)
21. Effectiveness of antimuscarinics and a beta-3 adrenoceptor agonist in patients with overactive bladder in a real-world setting.
Huang CK; Lin CC; Lin AT
Sci Rep; 2020 Jul; 10(1):11355. PubMed ID: 32647277
[TBL] [Abstract][Full Text] [Related]
22. Prospective Pilot Study of Mirabegron in Pediatric Patients with Overactive Bladder.
Blais AS; Nadeau G; Moore K; Genois L; Bolduc S
Eur Urol; 2016 Jul; 70(1):9-13. PubMed ID: 26876327
[TBL] [Abstract][Full Text] [Related]
23. Overactive Bladder and the β3-Adrenoceptor Agonists: Current Strategy and Future Prospects.
Giarenis I; Robinson D; Cardozo L
Drugs; 2015 Oct; 75(15):1707-13. PubMed ID: 26323339
[TBL] [Abstract][Full Text] [Related]
24. Pathophysiology, assessment, and treatment of overactive bladder symptoms in patients with interstitial cystitis/bladder pain syndrome.
Dobberfuhl AD
Neurourol Urodyn; 2022 Nov; 41(8):1958-1966. PubMed ID: 35607890
[TBL] [Abstract][Full Text] [Related]
25. Antimuscarinic Use in Females With Overactive Bladder Syndrome Increases the Risk of Depressive Disorder: A 3-Year Follow-up Study.
Chung SD; Weng SS; Huang CY; Lin HC; Kao LT
J Clin Pharmacol; 2017 Aug; 57(8):1064-1070. PubMed ID: 28378881
[TBL] [Abstract][Full Text] [Related]
26. Comparison of Therapeutic Efficacy and Urodynamic Findings of Solifenacin Succinate versus Mirabegron in Women with Overactive Bladder Syndrome: Results of a Randomized Controlled Study.
Vecchioli Scaldazza C; Morosetti C
Urol Int; 2016; 97(3):325-329. PubMed ID: 27092789
[TBL] [Abstract][Full Text] [Related]
27. Optimizing Nonsurgical Treatments of Overactive Bladder in the United States.
Brucker BM; Lee RK; Newman DK
Urology; 2020 Nov; 145():52-59. PubMed ID: 32598892
[TBL] [Abstract][Full Text] [Related]
28. Early investigational β3 adreno-receptor agonists for the management of the overactive bladder syndrome.
Thiagamoorthy G; Giarenis I; Cardozo L
Expert Opin Investig Drugs; 2015; 24(10):1299-306. PubMed ID: 26292923
[TBL] [Abstract][Full Text] [Related]
29. A drug safety evaluation of mirabegron in the management of overactive bladder.
Robinson D; Thiagamoorthy G; Cardozo L
Expert Opin Drug Saf; 2016 May; 15(5):689-96. PubMed ID: 26980445
[TBL] [Abstract][Full Text] [Related]
30. Bladder base/trigone injection is safe and as effective as bladder body injection of onabotulinumtoxinA for idiopathic detrusor overactivity refractory to antimuscarinics.
Kuo HC
Neurourol Urodyn; 2011 Sep; 30(7):1242-8. PubMed ID: 21560152
[TBL] [Abstract][Full Text] [Related]
31. Comparative Efficacy and Tolerability of Antimuscarinic Agents and the Selective β3-Adrenoceptor Agonist, Mirabegron, for the Treatment of Overactive Bladder: Which is More Preferable as an Initial Treatment?
Kobayashi M; Nukui A; Kamai T
Low Urin Tract Symptoms; 2018 May; 10(2):158-166. PubMed ID: 28009939
[TBL] [Abstract][Full Text] [Related]
32. Current pharmacotherapy of overactive bladder.
Kreydin EI; Gomes CM; Cruz F
Int Braz J Urol; 2021; 47(6):1091-1107. PubMed ID: 34003613
[TBL] [Abstract][Full Text] [Related]
33. Systematic literature review of clinical trials evaluating pharmacotherapy for overactive bladder in elderly patients: An assessment of trial quality.
Kistler KD; Xu Y; Zou KH; Ntanios F; Chapman DS; Luo X
Neurourol Urodyn; 2018 Jan; 37(1):54-66. PubMed ID: 28763112
[TBL] [Abstract][Full Text] [Related]
34. OnabotulinumtoxinA improves health-related quality of life in patients with urinary incontinence due to idiopathic overactive bladder: a 36-week, double-blind, placebo-controlled, randomized, dose-ranging trial.
Fowler CJ; Auerbach S; Ginsberg D; Hale D; Radziszewski P; Rechberger T; Patel VD; Zhou J; Thompson C; Kowalski JW
Eur Urol; 2012 Jul; 62(1):148-57. PubMed ID: 22464310
[TBL] [Abstract][Full Text] [Related]
35. [Not Available].
Perucchini D; Betschart C; Fink D; Scheiner DA
Praxis (Bern 1994); 2017 Jan; 106(1):37-44. PubMed ID: 28055318
[No Abstract] [Full Text] [Related]
36. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony).
Abrams P; Kelleher C; Staskin D; Rechberger T; Kay R; Martina R; Newgreen D; Paireddy A; van Maanen R; Ridder A
Eur Urol; 2015 Mar; 67(3):577-88. PubMed ID: 24612659
[TBL] [Abstract][Full Text] [Related]
37. Current and future pharmacotherapy for treating overactive bladder.
Thiagamoorthy G; Cardozo L; Robinson D
Expert Opin Pharmacother; 2016 Jul; 17(10):1317-25. PubMed ID: 27253972
[TBL] [Abstract][Full Text] [Related]
38. Emerging drugs for treatment of overactive bladder and detrusor overactivity.
Drake MJ
Expert Opin Emerg Drugs; 2008 Sep; 13(3):431-46. PubMed ID: 18764721
[TBL] [Abstract][Full Text] [Related]
39. Overactive bladder syndrome presentations at the 31st International Urogynecological Association Annual Meeting.
Miller JJ; Sand AP
Curr Urol Rep; 2007 Nov; 8(6):435-40. PubMed ID: 18042321
[TBL] [Abstract][Full Text] [Related]
40. [Overactive bladder-which treatment when?].
Pannek J
Urologe A; 2017 Dec; 56(12):1532-1538. PubMed ID: 29043374
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
